Bookmarks
Health resource utilisation and cost burden of individuals with Amyotrophic Lateral Sclerosis (ALS) in England
Safe People
Biogen
Commercial
Li Li - Chief Investigator - BiogenKatie Stenson - Corresponding Applicant - BiogenKim Heithoff - Collaborator - BiogenSusan Eaton - Collaborator - BiogenVarant Kupelian - Collaborator - Biogen
Safe Projects
CPRD25
Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) is a condition affecting the
To describe and estimate the HCRU (frequency) and costs of outpatient visits, hospitalisations, medications, medical procedures, and assistive devices among adults newly diagnosed with ALS in England. The diseased group consists of those newly diagnosed with ALS based on Read/SNOMED codes and having no encounters with ALS diagnostic codes for 6 months prior to the index date. We will then match cases to controls without ALS diagnosis by age (at
12/05/2021
Safe Data
HES Admitted Patient Care
HES Outpatient
ONS Death Registration Data
Patient Level Index of Multiple Deprivation
Practice Level Index of Multiple Deprivation
Safe Setting
Release